ArticleJournal of the Endocrine Society2025
Plasma Steroid Profiles in Individuals With Class II/III Obesity: Association With Weight Loss After Metabolic Surgery.
Article in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasma Steroid Profiles in Individuals With Class II/III Obesity: Association With Weight Loss After Metabolic Surgery.Journal of the Endocrine Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Although steroid metabolism is altered in individuals with obesity, comprehensive profiles of steroid metabolites remain unexplored, some of which may be related to weight loss after metabolic surgery. Objective: We aimed to characterize comprehensive steroid profiles in individuals with class II/III obesity (body mass index ≥35 kg/m Methods: Using liquid chromatography-tandem mass spectrometry, we measured 27 plasma steroid metabolites in individuals with class II/III obesity (n = 93), healthy controls (n = 15), and those after LSG (n = 20). Results: Discriminant analysis revealed distinct steroid profiles between individuals with class II/III obesity and healthy controls, with statistical significance for 9 metabolites in men (n = 53) and 11 in premenopausal women (n = 44). One year after LSG, the insufficient and sufficient weight loss groups (percent total weight loss (%TWL) < 20%; n = 10 and %TWL ≥ 20%; n = 26) showed distinct preoperative steroid profiles. Preoperative 17α-hydroxypregnenolone (17α-OHPreg) levels, which were lower in individuals with class II/III obesity, were the most significant factor contributing to this distinction, and remained significantly lower in the insufficient weight loss group even after adjusting for confounders ( Conclusion: This study is the first detailed analysis of comprehensive steroid profiles in individuals with class II/III obesity and suggests that lower preoperative 17α-OHPreg levels are associated with insufficient weight loss after LSG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.